It is well known that activation of the extracellular signal regulated kinase (ERK)/mitogen-activated protein kinase (MAPK) and AKT/mammalian target of rapamycin (AKT/mTOR) pathways play a crucial role in the control of cell growth and survival in ovarian cancer and inhibition of these pathways leads to the inhibition of ovarian cancer growth [21, 22]. This evidence concerns the gene AKT1 and ovarian carcinoma.